Who Generates More Revenue? Bio-Techne Corporation or BioMarin Pharmaceutical Inc.

Revenue Race: Bio-Techne vs. BioMarin

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, BioMarin Pharmaceutical Inc. has consistently outpaced Bio-Techne Corporation in annual revenue. From 2014 to 2023, BioMarin's revenue surged by over 220%, peaking at approximately $2.42 billion in 2023. In contrast, Bio-Techne's revenue grew by around 220% as well, reaching about $1.16 billion in the same year.

BioMarin's robust growth can be attributed to its innovative therapies and strategic market expansions, while Bio-Techne has steadily increased its market share through diversification and acquisitions. Notably, BioMarin's revenue in 2023 was more than double that of Bio-Techne, highlighting its dominant position in the biotech sector. However, the data for 2024 is incomplete, leaving room for speculation on future trends. As these companies continue to innovate, the revenue race remains a captivating narrative in the biotech industry.